Vericel Corp
VCELHealthcare|Biotechnology|USA
$47.00
-1.32 (-2.73%)
DCF (FCF)
$9.33
Tangible Book
$6.88
Graham Number
$8.06
Earnings Power
$1.32
Clinical Trials (15)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06915233 A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle | Chondral Defect, Articular Cartilage Defect | P3 | Recruiting | 309 | RCT, Open-label | autologous cultured chondrocytes on porcine collagen membrane |
| NCT03588975 A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee | Chondral Defect, Osteochondritis Dissecans (OCD) | P3 | Recruiting | 45 | RCT, Open-label | MACI |
| NCT00158613 Study of the Treatment of Articular Repair (STAR) | Articular Cartilage | P4 | Completed | 126 | Open-label | Carticel (autologous cultured chondrocyte) implantation |
| NCT00505219 Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head | Osteonecrosis | P3 | Completed | 11 | RCT, Single-blind | Ixmyelocel-T |
| NCT00719576 Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the Knee | Articular Cartilage Defect | P3 | Completed | 144 | RCT, Open-label | autologous cultured chondrocytes on porcine collagen membrane |
| NCT01483898 An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI) | Critical Limb Ischemia | P3 | Completed | 41 | RCT, Double-blind | Ixmyelocel-T |
| NCT00468000 Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia | Peripheral Arterial Disease | P2 | Completed | 86 | RCT, Double-blind | Ixmyelocel-T, Placebo |
| NCT00765518 Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM) | Dilated Cardiomyopathy | P2 | Completed | 40 | RCT, Open-label | Ixmyelocel-T |
| NCT00424567 Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures. | Fracture, Ununited, Pseudarthrosis | P1P2 | Terminated | 36 | Open-label | Cultured Bone Marrow Tissue |
| NCT01020968 Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy | Dilated Cardiomyopathy | P2 | Completed | 22 | RCT, Open-label | Ixmyelocel-T |
| NCT00755911 Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy | Alveolar Bone Loss | P1P2 | Completed | 24 | RCT, Open-label | Tissue Repair Cells (TRC) |
| NCT00797550 Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion | Single Level Posterolateral Spinal Fusion | P1P2 | Terminated | 2 | RCT, Open-label | Bone Repair Cells (BRCs) |
| NCT01670981 An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM) | Ischemic Dilated Cardiomyopathy (IDCM) | P2 | Completed | 114 | RCT, Double-blind | ixmyelocel-T |
| NCT01251588 Extension Study for Participants of MACI00206 Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Knee | Articular Cartilage Defects | Completed | 128 | — | autologous cultured chondrocytes on porcine collagen membrane | |
| NCT00140634 The Objectives of the Cartilage Repair Registry is to Report Long Term Efficacy and Safety of Cartilage Repair Procedures in Registry Patients | Articular Cartilage, Cartilage Diseases | Completed | 2,233 | — | Carticel (autologous cultured chondrocyte) implantation |